3.22
+1.34(+71.28%)
Currency In USD
| Previous Close | 1.88 |
| Open | 2.17 |
| Day High | 3.47 |
| Day Low | 2 |
| 52-Week High | 17.68 |
| 52-Week Low | 1.36 |
| Volume | 56.28M |
| Average Volume | 3.59M |
| Market Cap | 2.6M |
| PE | -1.04 |
| EPS | -3.1 |
| Moving Average 50 Days | 3.05 |
| Moving Average 200 Days | 5.42 |
| Change | 1.34 |
If you invested $1000 in 60 Degrees Pharmaceuticals, Inc. (SXTP) since IPO date, it would be worth $11.47 as of March 11, 2026 at a share price of $3.22. Whereas If you bought $1000 worth of 60 Degrees Pharmaceuticals, Inc. (SXTP) shares 2 years ago, it would be worth $198.77 as of March 11, 2026 at a share price of $3.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
GlobeNewswire Inc.
11 hours ago
All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publicationCompany calls for existing babesiosis treatment guidelines to be reviewed in light o
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
GlobeNewswire Inc.
Feb 02, 2026 1:01 PM GMT
GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company’s marketing strategyPartnership will improve the affordability of ARAKODA at over
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
GlobeNewswire Inc.
Jan 28, 2026 1:01 PM GMT
Company ready to commence regulatory process to secure access to U.S. market for Australian Chestnut Extract as a botanical product for non-prescription usesWASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXT